1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Schizophrenia in 4 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Adverse events, including mild to moderate sporadic orthostatic hypotension and/or nausea and vomiting, were most commonly observed after the initial drug dose and decreased after repeated dosing." | 2.69 | Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia. ( Cutler, NR; Eldon, MA; Feng, MR; Hourani, J; Jhee, SS; Posvar, E; Sedman, AJ; Sramek, JJ, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Napolitano, F | 1 |
| Booth Warren, E | 1 |
| Migliarini, S | 1 |
| Punzo, D | 1 |
| Errico, F | 1 |
| Li, Q | 1 |
| Thiolat, ML | 1 |
| Vescovi, AL | 1 |
| Calabresi, P | 1 |
| Bezard, E | 1 |
| Morelli, M | 1 |
| Konradi, C | 1 |
| Pasqualetti, M | 1 |
| Usiello, A | 1 |
| Bloem, BR | 1 |
| Beckley, DJ | 1 |
| van Vugt, JP | 1 |
| van Dijk, JG | 1 |
| Remler, MP | 1 |
| Langston, JW | 1 |
| Roos, RA | 1 |
| Sramek, JJ | 1 |
| Eldon, MA | 1 |
| Posvar, E | 1 |
| Feng, MR | 1 |
| Jhee, SS | 1 |
| Hourani, J | 1 |
| Sedman, AJ | 1 |
| Cutler, NR | 1 |
| Donaldson, J | 1 |
1 review available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Schizophrenia
| Article | Year |
|---|---|
The physiopathologic significance of manganese in brain: its relation to schizophrenia and neurodegenerative disorders.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Blood Glucose; Brain; Brain Chemistry; Chile; | 1987 |
1 trial available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Schizophrenia
| Article | Year |
|---|---|
Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in patients with schizophrenia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adolescent; Adult; Antipsychotic Agents; Female; Human | 1998 |
2 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Schizophrenia
| Article | Year |
|---|---|
Decreased Rhes mRNA levels in the brain of patients with Parkinson's disease and MPTP-treated macaques.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; Aged, 80 and over; Animals; Bipolar Disorder; Br | 2017 |
Long latency postural reflexes are under supraspinal dopaminergic control.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Age of Onset; Antiparkinson Agents; Antipsychot | 1995 |